MASH (Metabolic Steatohepatitis) - Staging, Monitoring, and New Treatments
MASH is the subgroup of metabolic liver disease where fat is joined by inflammation and a much higher risk of fibrosis progression. It matters commercially and clinically because new treatment pathways make repeat monitoring more valuable than ever.
Content note
Prepared by the Elastography Australia clinical education team for informational purposes and pathway literacy. It is not patient-specific medical advice.
- MASH represents the higher-risk inflammatory subgroup within metabolic liver disease.
- Fibrosis stage is central to management because F2 and above changes the urgency of treatment and surveillance planning.
- New therapies increase demand for structured, repeatable staging and monitoring workflows.
From NASH to MASH
The terminology shift from NASH to MASH reflects broader nomenclature changes in metabolic liver disease, but the practical question remains the same: which patients have moved beyond simple steatosis into clinically significant inflammatory and fibrotic disease.
For clinicians, MASH is the point where non-invasive staging becomes even more valuable because management decisions become more serious and longitudinal monitoring becomes essential.
Why fibrosis stage matters so much in MASH
The playbook positions fibrosis stage, especially F2 and beyond, as the management hinge point. This is where treatment pathways, surveillance, and referral urgency all start to change.
Elastography therefore becomes less about broad screening alone and more about tracking disease burden, response, and escalation thresholds over time.
What new therapies change
Resmetirom is highlighted in the research and playbook as a major demand catalyst because approved or emerging therapies create a larger cohort that needs baseline staging and serial follow-up.
That strengthens the case for an accessible elastography workflow in both specialist and metabolic practice, especially where long waits or fragmented access would otherwise slow care.
Monitoring and surveillance
Patients with MASH need follow-up pathways that focus on fibrosis progression, regression, and the possibility of cirrhosis or HCC risk over time. Elastography is particularly useful here because it can be repeated without the burden of biopsy.